SCHEMBL832584

SCHEMBL832584

CCOc1nc(-c2ccc(Cl)cc2)cc(C(F)(F)F)c1C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
RXFP1 Q9HBX9 2/20 0.48
POLB P06746 2/20 0.46
MAPT P10636 2/20 0.46
CTRC Q99895 2/20 0.42
ACHE P22303 1/20 0.42
HPGD P15428 3/20 0.41
KDM4E B2RXH2 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
MEN1 O00255 1/20 0.41
LMNA P02545 1/20 0.41
RAB9A P51151 1/20 0.41
KMT2A Q03164 1/20 0.41
ATM Q13315 1/20 0.41
DHODH Q02127 3/20 0.40
EGFR P00533 1/20 0.40
KMO O15229 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL830425 0.89 ALDH1A1 (0.51) ALDH1A1L3MBTL1RXFP1MAPTHPGD
SCHEMBL830078 0.89 ALDH1A1 (0.46) ALDH1A1L3MBTL1KMO
SCHEMBL829557 0.88 XDH (0.45) ALDH1A1L3MBTL1RXFP1POLBMAPT
SCHEMBL832846 0.87 MAPT (0.43) ALDH1A1L3MBTL1RXFP1POLBMAPT
SCHEMBL831291 0.84 POLB (0.43) ALDH1A1L3MBTL1RXFP1POLBMAPT
SCHEMBL830844 0.83 ALDH1A1 (0.49) ALDH1A1L3MBTL1RXFP1MAPTHPGD
SCHEMBL829626 0.83 ALDH1A1 (0.50) ALDH1A1L3MBTL1RXFP1MAPTHPGD
SCHEMBL830022 0.81 POLB (0.42) ALDH1A1L3MBTL1RXFP1POLBMAPT
SCHEMBL832712 0.79 MAPT (0.41) ALDH1A1L3MBTL1RXFP1POLBMAPT
SCHEMBL831302 0.77 XDH (0.48) ALDH1A1L3MBTL1RXFP1POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143411-B2 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2012-03-27 US disclosed
US-8143411-B2 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2012-03-27 US disclosed
US-8143411-B2 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2012-03-27 US disclosed
US-20100234432-A1 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2010-09-16 US disclosed
US-20100234432-A1 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2010-09-16 US disclosed
US-20100234432-A1 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2010-09-16 US disclosed
WO-2009033561-A1 SUBSTITUTED 6-PHEYLNICOTINIC ACIDS AND THE USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-03-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234432-A1 Substituted 6-phenylnicotinic acids and their use SLC5A6, FABP3, NAPRT ALDH1A1 1238/4885L3MBTL1 823/4885RXFP1 4312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.